Literature DB >> 26618043

Cortisol Supplement Combined with Psychotherapy and Citalopram Improves Depression Outcomes in Patients with Hypocortisolism after Traumatic Brain Injury.

Lanlan Luo1, Yan Chai2, Rongcai Jiang3, Xin Chen3, Tao Yan1.   

Abstract

Depression is one of the most prevalent psychiatric disorders in people with Traumatic brain injury (TBI). Depression after TBI is closely related with social and psychological factors and hypothalamic-pituitary -adrenal (HPA) axis dysfunction. However, there is a lack of evidence regarding effective treatment approaches for depression. A total of 68 patients with depression following closed TBI were recruited. Glasgow Coma Scale score (GCS) was employed to demonstrate the severity of neurological deficits and Glasgow Outcome Scale (GOS) was employed to measure functional outcome after TBI. The severity of depression was quantified using the Beck Depression Inventory-II (BDI-II) in line with DSM-IV. Citalopram and Prednisone were administered to subjects with normal cortisol levels or hypocortisolism separately, based on psychotherapeutic interventions. We investigated the relationship between degree of depression of TBI patients and the severity and progression of TBI with the therapeutic effects of Citalopram in combination with psychotherapeutic and Prednisone in depressed patients. There was no relationship between the severity of depression and the severity and progression of TBI. The basic treatment of psychotherapeutic interventions could partially relieve depressive symptoms. Combination of psychotherapeutic support and Citalopram significantly improved depressive symptoms in patients with normal cortisol levels, but not in hypocortisolic patients. Combination of Prednisone administration with psychotherapeutic treatment and Citalopram significantly improved depression outcome in hypocortisolic patients after TBI. Hypocortisolism after TBI may regulate depression. Combination of Prednisone with psychotherapeutic treatment and Citalopram may provide better therapeutic effects in depression patients with hypocortisolism after TBI.

Entities:  

Keywords:  citalopram; cortisol supplement; depression; traumatic brain injury

Year:  2015        PMID: 26618043      PMCID: PMC4657813          DOI: 10.14336/AD.2015.0507

Source DB:  PubMed          Journal:  Aging Dis        ISSN: 2152-5250            Impact factor:   6.745


  47 in total

1.  Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes.

Authors:  Emmette R Hutchison; Elisa M Kawamoto; Dennis D Taub; Ashish Lal; Kotb Abdelmohsen; Yongqing Zhang; William H Wood; Elin Lehrmann; Simonetta Camandola; Kevin G Becker; Myriam Gorospe; Mark P Mattson
Journal:  Glia       Date:  2013-05-07       Impact factor: 7.452

2.  Hourly neurologic assessments for traumatic brain injury in the ICU.

Authors:  Jonathan Jay Stone; Sean Childs; Lindsay Erin Smith; Megan Battin; Peter J Papadakos; Jason H Huang
Journal:  Neurol Res       Date:  2014-02       Impact factor: 2.448

Review 3.  Hypopituitarism following traumatic brain injury.

Authors:  V Popovic; G Aimaretti; F F Casanueva; E Ghigo
Journal:  Growth Horm IGF Res       Date:  2005-03-21       Impact factor: 2.372

4.  Problems and changes after traumatic brain injury: differing perceptions within and between families.

Authors:  M M Cavallo; T Kay; O Ezrachi
Journal:  Brain Inj       Date:  1992 Jul-Aug       Impact factor: 2.311

5.  The epidemiology and impact of traumatic brain injury: a brief overview.

Authors:  Jean A Langlois; Wesley Rutland-Brown; Marlena M Wald
Journal:  J Head Trauma Rehabil       Date:  2006 Sep-Oct       Impact factor: 2.710

6.  The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death.

Authors:  R M Sapolsky
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

7.  Depression and loneliness in Jamaicans with sickle cell disease.

Authors:  Monika R Asnani; Raphael Fraser; Norma A Lewis; Marvin E Reid
Journal:  BMC Psychiatry       Date:  2010-06-07       Impact factor: 3.630

8.  The incidence of acute brain injury and serious impairment in a defined population.

Authors:  J F Kraus; M A Black; N Hessol; P Ley; W Rokaw; C Sullivan; S Bowers; S Knowlton; L Marshall
Journal:  Am J Epidemiol       Date:  1984-02       Impact factor: 4.897

9.  The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: a randomized trial.

Authors:  Douglas L Delahanty; Crystal Gabert-Quillen; Sarah A Ostrowski; Nicole R Nugent; Beth Fischer; Adam Morris; Roger K Pitman; John Bon; William Fallon
Journal:  CNS Spectr       Date:  2013-04       Impact factor: 3.790

10.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

View more
  3 in total

1.  A combined therapeutic regimen of citalopram and environmental enrichment ameliorates attentional set-shifting performance after brain trauma.

Authors:  Heather M Minchew; Hannah L Radabaugh; Megan L LaPorte; Kristin E Free; Jeffrey P Cheng; Corina O Bondi
Journal:  Eur J Pharmacol       Date:  2021-05-15       Impact factor: 5.195

Review 2.  Selective Serotonin Reuptake Inhibitors for Treating Neurocognitive and Neuropsychiatric Disorders Following Traumatic Brain Injury: An Evaluation of Current Evidence.

Authors:  John K Yue; John F Burke; Pavan S Upadhyayula; Ethan A Winkler; Hansen Deng; Caitlin K Robinson; Romain Pirracchio; Catherine G Suen; Sourabh Sharma; Adam R Ferguson; Laura B Ngwenya; Murray B Stein; Geoffrey T Manley; Phiroz E Tarapore
Journal:  Brain Sci       Date:  2017-07-25

3.  A systematic review on integrated care for traumatic brain injury, mental health, and substance use.

Authors:  Vincy Chan; Danielle Toccalino; Samira Omar; Riya Shah; Angela Colantonio
Journal:  PLoS One       Date:  2022-03-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.